Development and characterization of six new human papillary thyroid carcinoma cell lines

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages E243-E252

  Henderson, Ying C ^a   Ahn, Soon Hyun ^c   Ryu, Junsun ^d   Chen, Yunyun ^a   Williams, Michelle D ^b   El Naggar, Adel K ^b   Gagea, Mihai ^b   Schweppe, Rebecca E ^e   Haugen, Bryan R ^e   Lai, Stephen Y ^a,b   Clayman, Gary L ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Seoul National University Bundang Hospital   (South Korea)

^d National Cancer Center   (South Korea)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CARCINOGENICITY; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NRAS GENE; PAPILLARY THYROID CARCINOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SHORT TANDEM REPEAT; TELOMERASE REVERSE TRANSCRIPTASE GENE; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; GENETICS; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

MICROSATELLITE DNA; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMALS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; HUMANS; MICE; MICROSATELLITE REPEATS; MUTATION; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; TELOMERASE; THYROID GLAND; THYROID NEOPLASMS;

EID: 84928315289     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2624     Document Type: Article

References (31)

1. Cancer Facts, Figures 2014. American Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
2. LiVolsi VA Papillary thyroid carcinoma: An update. Mod Pathol. 2011; 24: S1-S9.
3. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: Thephase III DECISION trial. Proc 31st Annual Meeting of the American Society of Clinical Oncology, (June 20 Suppl), 2013.
4. Lloyd R, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head and Neck Pathol. 2011; 5: 51-56.
5. Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014; 99: 536-544.
6. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL. MEK Inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010; 9: 1968-1976.
7. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 2009; 15: 485-491.
8. Lehman TA, Bennett WP, Metcalf RA, et al. p53 Mutations, ras Mutations, and p53-Heat Shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991; 51: 4090-4096.
9. Ahn SH, Henderson Y, Kang Y, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg. 2008; 134: 190-197.
10. Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013; 4: 2185.
11. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013; 20: 603-610.
12. McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014; 111: E1600-E1609.
13. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008; 93: 4331-4341.
14. Zhao M, Sano D, Pickering CR, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011; 17: 7248-7264.
15. Park JY, Kim WY, Hwang TS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013; 24: 69-76.
16. Gupta N, Dasyam AK, Carty SE, et al. RAS mutations in thyroid fna specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab. 2013; 98: E914-E922.
17. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013; 98: E1852-E1860.
18. Meireles AM1, Preto A, Rocha AS. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid. 2007; 17: 707-715.
19. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69: 4885-4893.
20. Leroy B, Anderson M, Soussi T. TP53 Mutations in human cancer: Database reassessment and prospects for the next decade. Hum Mutat. 2014; 35: 672-688.
21. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014; 12: 979-986.
22. Simon D, Goretzki PE, Gorelev V, et al. Significance of P53 in human thyroid tumors. World J Surg. 1994; 18: 535-540;discussion 540-541
23. Lin C, Liang Y, Zhu H, Zhang J, Zhong X. R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway. Neurosci Lett. 2012; 529: 60-65.
24. Marlow LA, D'Innocenzi J, Zhang Y, et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol, Metab. 2010; 95: 5338-5347.
25. Yun JY, Kim YA, Choe JY, et al. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome. J Clin Pathol. 2014; 67: 125-133.
26. Carina V, Zito G, Pizzolanti G, et al. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: The putative upstream role of SOX2. Thyroid. 2013; 23: 829-837.
27. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer. 2011; 11: 761-774.
28. Karnoub AE, Weinberg RA. Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol. 2008; 9: 517-531.
29. Lee SR, Jung CK, Kim TE. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid. 2013; 23: 1416-1422.
30. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339: 959-961.
31. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem. 2011; 80: 437-471.